Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||APG-115 + Carboplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|APG-115||APG115|APG 115|Alrizomadlin||MDM2 Inhibitor 22||APG-115, a derivative of SAR405838, inhibits MDM2 and its interaction with p53, thereby stabilizing and activating wild-type p53, which may result in antitumor activity and also synergizes with PD-1 inhibitors (PMID: 28498808, PMID: 31779710).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|